Remdesivir

Kathryn Dzintars, Pharm.D., BCPS, Edina Avdic, Pharm.D.
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS
Remdesivir is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Remdesivir is approved for the treatment of coronavirus disease 2019 (COVID-19) in adult and pediatric patients (28 days of age and older, and who weigh at least 3 kg) who:
    • Require hospitalization
    • Have positive results of direct SARS-CoV-2 viral testing, who are not hospitalized, have mild to moderate symptoms, and are at high risk for progression to severe COVID-19, including hospitalization or death
  • Severe disease is defined as:
    • Patients with SpO2 ≤ 94% on room air, OR
    • Requiring supplemental oxygen, OR
    • Requiring mechanical ventilation, OR
    • Requiring extracorporeal membrane oxygenation (ECMO)

NON-FDA APPROVED USES

  • Nonhospitalized patients who are at high risk for disease progression may be given a 3-day course of remdesivir (200 mg IV on day 1, then 100 mg IV on days 2 and 3).

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Remdesivir is approved for the treatment of coronavirus disease 2019 (COVID-19) in adult and pediatric patients (28 days of age and older, and who weigh at least 3 kg) who:
    • Require hospitalization
    • Have positive results of direct SARS-CoV-2 viral testing, who are not hospitalized, have mild to moderate symptoms, and are at high risk for progression to severe COVID-19, including hospitalization or death
  • Severe disease is defined as:
    • Patients with SpO2 ≤ 94% on room air, OR
    • Requiring supplemental oxygen, OR
    • Requiring mechanical ventilation, OR
    • Requiring extracorporeal membrane oxygenation (ECMO)

NON-FDA APPROVED USES

  • Nonhospitalized patients who are at high risk for disease progression may be given a 3-day course of remdesivir (200 mg IV on day 1, then 100 mg IV on days 2 and 3).

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: May 24, 2022